Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    resonate
Show Display Options
Rank Status Study
1 Active, not recruiting A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: ofatumumab;   Drug: ibrutinib
2 Active, not recruiting A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: PCI-32765;   Drug: Chlorambucil
3 Active, not recruiting A Multicenter Phase 2 Study of PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
Conditions: Chronic Lymphocytic Leukemia With 17p Deletion;   Small Lymphocytic Lymphoma With 17p Deletion
Intervention: Drug: PCI-32765

Indicates status has not been verified in more than two years